Skip to main content

Pareto, DNA2.0 Partner on Synthetic Biology Applications

NEW YORK (GenomeWeb) – Synthetic biology startup Pareto Biotechnologies announced today a technology partnership with DNA2.0 to integrate their technologies to hasten the engineering of proteins in Pareto's pipeline.

Pareto, based in San Francisco, said it will merge its synthetic biology pipeline platform with DNA2.0's ProteinGPS engineering technology to identify and quantify protein genetic mutations for incorporation into iterative rounds of improved synthetic genes. Pareto will also leverage DNA2.0's technologies to "increase the efficacy of its own platform to generate flavors, fragrances, and cosmetics with improved and novel properties," it added in a statement.

Financial and other terms of the deal were not disclosed.

"Our deep understanding of the structures of these classes of enzymes, along with a statistical optimization algorithm from DNA2.0 gets us the best of both worlds: rational design and robust enzyme improvement," Pareto CEO Jamie Bacher said. "Through our relationship with DNA2.0, we'll be able to generate completely novel molecules with applicability to flavors and fragrances, cosmetics, and therapeutics."

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.